摘要
目的:对胸腔镜手术治疗慢性脓胸的效果与安全性进行观察分析。方法:选取2010年3月-2016年1月本院收治的慢性脓胸患者80例作为研究对象,按照随机数字表方法分为对照组和观察组,每组40例。对照组患者行传统开胸手术治疗,观察组患者行胸腔镜手术治疗。比较观察两组患者手术基本情况、手术疗效及术后并发症发生率。结果:观察组手术时间、出血量、住院时间及胸腔引流量均明显低于对照组,差异均有统计学意义(P<0.05);观察组手术治疗总有效率为95.00%,明显高于对照组的72.50%,差异有统计学意义(P<0.05);观察组术后并发症发生率为10.00%,明显低于对照组的27.50%,差异有统计学意义(P<0.05)。结论:胸腔镜手术治疗慢性脓胸的整体效果确切,手术时间短、出血量少、引流量少、住院时间短,且整体疗效可靠,并发症少,具有进一步推广的临床价值。
Objective:To observe and analyze the efficacy and safety of thoracoscopic surgery in the treatment of chronic empyema.Method:From March 2010 to January 2016,80 cases of chronic empyema in our hospital were selected as the research objects,they were divided into the control group and the observation group according to the random number table,each group had 40 cases.The control group was treated with traditional open chest surgery and the observation group was treated with thoracoscopic surgery.The operation of basic situation,operation curative effect and incidence of postoperative complications of two groups were observed and compared.Result:The operation time,blood loss,length of stay in hospital and thoracic drainage in the observation group were significantly lower than those of the control group,the differences were statistically significant(P〈0.05).The total effective rate of the observation group was 95.00%,which was significantly higher than 72.50% of the control group,the difference was statistically significant(P〈0.05).The incidence rate of postoperative complications of the observation group was 10.00%,which was significantly lower than 27.50% of the control group,the difference was statistically significant(P〈0.05).Conclusion:Exactly to the overall effect in the treatment of chronic pyothorax thoracoscope surgery,shorter operation time,less blood loss,less quantity of drainag,shorter hospitalization time and the overall curative effect is reliable,fewer complications,has a clinical value of further promotion.
出处
《中国医学创新》
CAS
2016年第21期120-123,共4页
Medical Innovation of China
关键词
慢性脓胸
胸腔镜手术
疗效
安全性
Chronic empyema
Thoracic surgery
Efficacy
Safety